The McGill University Health Centre (MUHC) is the first site in the world to launch a first-in-human phase 1 clinical trial ...

Novartis is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therap ...

Collaboration enables access to SHINE’s supply of lutetium-177 for Nucleus RadioPharma’s radioligand therapy for neuroendocrine tumors and prostate cancer ROCHESTER, Minn. & JANESVILLE, ...

The MUHC is the first site in the world to launch a first-in-human Phase I clinical trial evaluating a novel radioligand ...

For patients with metastatic prostate cancer who have exhausted initial or first-line treatments like hormone therapy (also called androgen deprivation therapy or ADT) and chemotherapy, a promising ...

PRINCETON, WV (WVNS) – Cancer services are being expanded at WVU Medicine Princeton Community Hospital. That’s according to a ...

Novartis launches Pluvicto, introducing a precision oncology treatment that delivers targeted radiation directly to cancer ...

A recent study published in The Lancet Regional Health—Europe estimates that the number of patients eligible for radioligand therapies (RLTs) in the EU-27 could increase from 10,700–13,200 in 2025 to ...

LONDON, June 16, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of a new Companies to Watch report, Radioligand ...

The U.S. Radiopharmaceutical CDMO Market is projected to grow from USD 1.29 Billion in 2025 to USD 3.00 Billion by 2035, while Europe is expected to expand from USD 1.09 Billion to USD 3.24 Billion, ...

Interim results from a phase 3 trial supported the use of the radioligand therapy 177 Lu-DOTATATE (Lutathera) as first-line therapy to treat high-grade gastroenteropancreatic neuroendocrine tumors.